FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ERBA Diagnostics Mannheim GmbH 		2. Issuer Name and Ticker or Trading Symbol

IVAX DIAGNOSTICS INC [ IVD ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

MALLAUSTR 69-73,  		3. Date of Earliest Transaction (MM/DD/YYYY)

7/1/2011
(Street)

MANNHEIM, 2M 68219
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 par value   7/1/2011     P    20000000   (1) (2) A $.75   40026313   D   (3) (6)  
Common Stock, $0.01 par value                  8400   I   By subsidiary   (4) (6)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Warrants (right to buy)   $.75   7/1/2011     P      20000000   (1)      7/1/2011   7/1/2016   Common Stock, $0.01 par value   20000000   $0   (1) 20000000   D   (5) (6)  

Explanation of Responses:
( 1)  On July 1, 2011, the issuer sold and issued to ERBA Diagnostics Mannheim GmbH ("ERBA"), in a privately negotiated transaction pursuant to a stock purchase agreement, an aggregate of 20,000,000 shares of the issuer's common stock at a purchase price of $0.75 per share and warrants to purchase an additional 20,000,000 shares of the issuer's common stock.
( 2)  These shares were acquired under a stock purchase agreement pursuant to which (a) 6,666,667 shares were issued and delivered to ERBA upon ERBA's payment to the issuer of $5,000,000.25, (b) 6,666,667 shares will be issued and delivered to ERBA upon ERBA's payment to the issuer of $5,000,000.25 by no later than January 1, 2012 and (c) 6,666,666 shares will be issued and delivered to ERBA upon ERBA's payment to the issuer of $4,999,999.50 by no later than July 1, 2012.
( 3)  These shares are held directly by ERBA and indirectly by Transasia Bio-medicals Ltd., its corporate parent, and Suresh H. Vazirani, its controlling shareholder.
( 4)  These shares are held by Erba Lachema s.r.o., a direct wholly-owned subsidiary of ERBA.
( 5)  These warrants are held directly by ERBA and indirectly by Transasia Bio-medicals Ltd., its corporate parent, and Suresh H. Vazirani, its controlling shareholder.
( 6)  All of the reporting persons may be deemed to have beneficial ownership with respect to these securities, however, each reporting person disclaims such beneficial ownership except to the extent of his or its pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ERBA Diagnostics Mannheim GmbH
MALLAUSTR 69-73
MANNHEIM, 2M 68219 		X X

Transasia Bio-Medicals Ltd.
TRANSASIA HOUSE
8 CHANDIVALI STUDIO ROAD
MUMBAI, IN 400072
X

Erba Lachema s.r.o.
KARASEK 1D
BRNO, 2N 62133
X

Vazirani Suresh H.
TRANSASIA HOUSE
8 CHANDIVALI STUDIO ROAD
MUMBAI, IN 400072 		X X Executive Chairman of Board
DUDANI KISHORE
TRANSASIA HOUSE
8 CHANDIVALI STUDIO ROAD
MUMBAI, IN 400072 		X X


Signatures
ERBA Diagnostic Mannheim GmbH, By: /s/ Suresh Vazirani, Chief Executive Officer and Managing Director 7/5/2011
** Signature of Reporting Person Date

Transasia Bio-Medicals Ltd., By: /s/ Suresh Vazirani, Managing Director 7/5/2011
** Signature of Reporting Person Date

Erba Lachema s.r.o, By: /s/ Suresh Vazirani, Statutory Body 7/5/2011
** Signature of Reporting Person Date

/s/ Suresh Vazirani 7/5/2011
** Signature of Reporting Person Date

/s/ Kishore Dudani 7/5/2011
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Ivax Diagnostics (AMEX:IVD)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Ivax Diagnostics Charts.
Ivax Diagnostics (AMEX:IVD)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Ivax Diagnostics Charts.